During a plenary session on Tuesday, April 12, four researchers discussed the latest advances in immuno-oncology, including developments in the understanding of immunotherapy modalities, efficacy, and combination strategies. Carl H. June, MD, FAACR, chaired the session.

The Annual Meeting’s final Clinical Trials Plenary Session featured trials of immunotherapy drug combinations that could benefit patients who don’t respond to single-agent immunotherapy or chemotherapy combinations. Timothy A. Yap, MD, PhD, chaired the session.

Organized by the AACR Chemistry in Cancer Research working group, this year’s three “New Drugs on the Horizon” sessions featured first disclosures of the discovery and structure of 12 novel agents.

Mariana C. Stern, PhD, led a plenary session featuring cancer researchers from around the world who discussed the integration of complex data and diversity to achieve better health equity.

Outgoing AACR President David A. Tuveson, MD, PhD, FAACR, discussed the unique challenges in the fight against pancreatic cancer and what it will take to achieve the aggressive targets of the Cancer Moonshot initiative in this patient population.

The Opening Plenary Session at the AACR Annual Meeting 2022 featured five state-of-the-art scientific presentations and a special lecture on the future of cancer research by Charles L. Sawyers, MD, FAACR.

Catriona H. M. Jamieson, MD, PhD, previews the Precancer Discover Science plenary, which examined new perspectives on cancer prevention, an integral part of the AACR’s research and health policy efforts.